en
×

分享给微信好友或者朋友圈

使用微信“扫一扫”功能。
通讯作者:

钱唯韵,E⁃mail:winter_1988524@126.

中图分类号:R589

文献标识码:A

文章编号:1007-4368(2021)05-725-05

DOI:10.7655/NYDXBNS20210515

参考文献 1
KJELDSEN L,JOHNSEN A H,SENGELOV H,et al.Iso⁃ lation and primary structure of NGAL,a novel protein as⁃ sociated with human neutrophil gelatinase[J].J Biol Chem,1993,268(14):10425-10432
参考文献 2
NA G Y,YOON S R,AN J,et al.The relationship be⁃ tween circulating neutrophil gelatinase ⁃ associated lipo⁃ calin and early alteration of metabolic parameters is asso⁃ ciated with dietary saturated fat intake in non⁃diabetic Ko⁃ rean women[J].Endocr J,2017,64(3):303-314
参考文献 3
BHUSAL A,RAHMAN M H,LEE W H,et al.Paradoxi⁃ cal role of lipocalin⁃2 in metabolic disorders and neurolog⁃ ical complications[J].Biochem Pharmacol,2019,169:113626
参考文献 4
梁利民,徐鹤翔,郑吉顺,等.RDW、NLR联合MELD评分评估失代偿期肝硬化患者预后的临床价值[J].南京医科大学学报(自然科学版),2020,40(2):217-222
参考文献 5
CHEN Y,YU C Y,DENG W M.The role of pro⁃inflamma⁃ tory cytokines in lipid metabolism of metabolic diseases [J].Int Rev Immunol,2019,38(6):249-266
参考文献 6
SYAUQY A,HSU C Y,RAU H H,et al.Association of di⁃ etary patterns,anthropometric measurements,and meta⁃ bolic parameters with C⁃reactive protein and neutrophil⁃to ⁃ lymphocyte ratio in middle ⁃ aged and older adults with metabolic syndrome in Taiwan:a cross ⁃ sectional study [J].Nutr J,2018,17(1):106
参考文献 7
ENGIN A.The definition and prevalence of obesity and metabolic syndrome[J].Adv Exp Med Biol,2017,960:1-17
参考文献 8
WANG Y,LAM K S,KRAEGEN E W,et al.Lipocalin⁃2 is an inflammatory marker closely associated with obesity,insulin resistance,and hyperglycemia in humans[J].Clin Chem,2007,53(1):34-41
参考文献 9
AUGUET T,QUINTERO Y,TERRA X,et a1.Upregula⁃ tion of lipocalin 2 in adipose tissues of severely obese women:positive relationship with proinflammatory cyto⁃ kines[J].Obesity(Silver Spring),2011,19(12):2295-2300
参考文献 10
PRADEEP A R,NAGPAL K,KARVEKAR S,et al.Lev⁃ els of lipocalin ⁃ 2 in crevicular fluid and tear fluid in chronic periodontitis and obesity subjects[J].J Investig Clin Dent,2016,7(4):376-382
参考文献 11
MOSIALOU I,SHIKHEL S,LUO N,et al.Lipocalin ⁃ 2 counteracts metabolic dysregulation in obesity and diabe⁃ tes[J].J Exp Med,2020,217(10):e20191261
参考文献 12
SONG E,FAN P,HUANG B,et al.Deamidated lipocalin⁃ 2 induces endothelial dysfunction and hypertension in di⁃ etary obese mice[J].J Am Heart Assoc,2014,3(2):e000837
参考文献 13
ABELLA V,SCOTECE M,CONDE J,et al.The potential of lipocalin ⁃ 2/NGAL as biomarker for inflammatory and metabolic diseases[J].Biomarkers,2015,20(8):565-571
参考文献 14
EILENBERG W,STOJKOVIC S,PIECHOTA ⁃ POLANC⁃ ZYK A,et al.Neutrophil gelatinase associated lipocalin(NGAL)is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment[J].Car⁃ diovasc Diabetol,2017,16(1):98
参考文献 15
ZHANG D,YE S,PAN T.The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J].PeerJ,2019,7:e7079
参考文献 16
SEIBERT F S,SITZ M,PASSFALL J,et al.Prognostic val⁃ ue of urinary calprotectin,NGAL and KIM ⁃ 1 in chronic kidney disease[J].Kidney Blood Press Res,2018,43(4):1255-1262
参考文献 17
YUAN G,QIAN W,PAN R,et al.Reduced circulating oxytocin and high ⁃molecular ⁃weight adiponectin are risk factors for metabolic syndrome[J].Endocr J,2016,63(7):655-662
参考文献 18
LIU C C,KO H J,LIU W S,et al.Neutrophil⁃to⁃lympho⁃ cyte ratio as a predictive marker of metabolic syndrome [J].Medicine(Baltimore),2019,98(43):e17537
参考文献 19
VICHAYA E G,GROSS P S,ESTRADA D J,et al.Lipo⁃ calin ⁃2 is dispensable in inflammation ⁃induced sickness and depression ⁃ like behavior[J].Psychopharmacology(Berl),2019,236(10):2975-2982
参考文献 20
SINGH R G,NGUYEN N N,CERVANTES A,et al.Cir⁃ culating levels of lipocalin⁃2 are associated with fatty pan⁃ creas but not fatty liver[J].Peptides,2019,119:170117
参考文献 21
JAHANGIRY L,FARHANGI M A,REZAEI F.Framing⁃ ham risk score for estimation of 10⁃years of cardiovascu⁃ lar diseases risk in patients with metabolic syndrome[J].J Health Popul Nutr,2017,36(1):36
目录contents

    摘要

    目的:观察血清中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase⁃associated lipocalin,NGAL)水平与中性粒细胞⁃淋巴细胞比值(neutrophil⁃lymphocyte ratio,NLR)的相关性,探讨 NGAL 联合 NLR 对代谢综合征(metabolic syndrome, MS)诊断的预测价值。方法:选取本院非MS(Non⁃MS)组及MS组各60例,所有研究对象行口服葡萄糖耐量试验(oral glucose tolerance test,OGTT)和胰岛素释放试验,检测NGAL、NLR、血糖、血脂等相关生化指标。结果:MS组血清NGAL水平高于Non⁃ MS组(P < 0.01)。NGAL与体重指数(BMI)、腰围(WC)、腰臀比(WHR)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、OGTT 2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、HOMA⁃IR、NLR呈正相关,与高密度脂蛋白胆固醇(high density lipop⁃ mtein cholesterin,HDL⁃C)及胰岛β细胞功能(HOMA⁃β)呈负相关(P<0.05或P<0.01)。Logistic回归分析显示,随着血清NGAL 及NLR水平升高,MS的发病风险呈上升趋势(P<0.05)。ROC曲线分析提示,NGAL联合NLR预测MS的曲线下面积(AUC)为 0.683(95%CI:0.592~0.765),优于单用NGAL(AUC=0.664,95%CI:0.573~0.748)]NLR(AUC=0.598,95%CI:0.505~0.687)(P< 0.01)。结论:MS患者NGAL水平与NLR呈正相关,NGAL联合NLR预测MS优于单独使用NGAL及NLR。

  • 中性粒细胞明胶酶相关脂质运载蛋白(neutro⁃ phil gelatinase⁃associated lipocalin,NGAL)是丹麦科学家Kjeldsen等[1] 利用免疫沉淀法及免疫印迹法在中性粒细胞中发现的,其与明胶酶B即基质金属蛋白酶9(matrix metalloproteinase⁃9,MMP⁃9)功能密切相关。由于它是脂质运载蛋白lipocalin家族的2号成员,因此也被称为lipocatin⁃2。NGAL广泛分布于人体各种组织,包括肺、肝脏、胸腺、肾脏、小肠、中性粒细胞、巨噬细胞以及脂肪细胞,是新发现的一类脂肪细胞因子。既往研究主要围绕其与感染性疾病、肿瘤和肾功能损害间的关系,近年来的研究发现其与代谢综合征(metabolic syndrome,MS)相关的肥胖、胰岛素抵抗密切相关,研究显示MS患者血清NGAL水平上升,血清NGAL可预测MS的发生风险[2-3]

  • 中性粒细胞⁃淋巴细胞比值(neutrophil⁃lympho⁃ cyte ratio,NLR)反映了中性粒细胞与淋巴细胞计数的相对变化。近年来作为新兴的炎症标志物,因其检测简便、非侵入性和低成本在多领域受到国内外学者关注,已被广泛应用于肿瘤、心血管系统、呼吸系统等领域[4]

  • 慢性炎症状态是MS主要的病理生理机制[5],有研究显示NLR水平在MS患者中升高,其与MS的发生及严重程度密切相关[6]。综合上述研究结果表明,NAGL与NLR均是MS的危险因素,两者通过不同的机制促进MS的发生发展。然而目前国内外尚未见有关NGAL联合NLR预测MS的报道。基于此,本研究旨在探讨NGAL及NLR在MS风险预测中的价值,为MS的早期临床防治提供依据。

  • 1 对象和方法

  • 1.1 对象

  • 选取2016年1月—2018年12月于苏州大学附属第三医院体检或就诊的汉族患者共120例,根据2005年国际糖尿病联盟(International Diabetes Fed⁃ eration,IDF)诊断标准分为MS组及非MS(Non⁃MS) 组各60例,其中,男79例,女41例,平均年龄 (46.29±11.41)岁。MS诊断标准参考2005年IDF全球共识定义,即必须具备中心型肥胖[腰围(waist circumference,WC)切点男≥90cm,女≥80cm]及下列4个因素中的任意2项:①甘油三酯(triglyceride,TG)水平升高(>1.7mmol/L);②高密度脂蛋白胆固醇(high density lipoprotein cholesterin,HDL⁃C)水平降低(男<1.03mmol/L或女<1.29mmol/L);③空腹血糖(fasting plasma glucose,FPG)升高(≥5.6mmol/L) 或已被诊断为2型糖尿病;④血压升高[收缩压(sys⁃ tolic blood pressure,SBP)≥130mmHg或舒张压(dia⁃ stolic blood pressure,DBP)≥85mmHg]或已被诊断为高血压病。排除标准:近期服用降糖或降脂或降压药物者;肝肾功能异常者;甲状腺功能异常及其他自身免疫性疾病和肿瘤等病史者;女性妊娠期及哺乳期者。本研究经伦理委员会批准并知情同意。

  • 1.2 方法

  • 1.2.1 人体测量

  • 由专人测定身高、体重、WC、臀围(hip circum⁃ ference,HC)及血压,计算体重指数(body mass in⁃ dex,BMI)及腰臀比(waist⁃to⁃hip ratio,WHR)。

  • 1.2.2 实验室检查

  • 研究对象于试验前晚禁食8~12h,次日行75g口服葡萄糖耐量试验(oral glucose tolerance test, OGTT),采静脉血测定FPG、OGTT2h血糖(2h post⁃ OGTT glucose,2hPG)(葡萄糖氧化酶法)及空腹胰岛素(fasting insulin,FIns)、OGTT2h胰岛素(2h post⁃ OGTT insulin,2hIns)(放免法)。采用高效液相层析法测定糖化血红蛋白(glycosylated hemoglobin, HbA1c),采用酶法测定TG、总胆固醇(total choles⁃ terol,TC)、HDL⁃C、低密度脂蛋白胆固醇(lowdensity lipoprotein cholesterol,LDL⁃C)。NGAL水平采用胶乳增强免疫比浊法测定(浙江达美生物技术有限公司)。

  • 1.2.3 计算各指数

  • 采用稳态模式评估法来评估胰岛素抵抗(ho⁃ meostasis model of insulin resistance,HOMA⁃IR)指数和胰岛β细胞功能(homeostasis model of β⁃cell func⁃ tion,HOMA ⁃β)指数:HOMA ⁃ IR=FPG × FINS/22.5, HOMA⁃β=FINS×20(/FPG-3.5)。

  • 1.3 统计学方法

  • 所有数据统计分析均运用软件SPSS16.0。正态分布的数据用均数±标准差(x- ± s)表示。非正态分布数据以中位数(四分位数)[MP25P75)]表示,对非正态分布数据予对数转换,符合正态分布后行统计分析。计量资料两组间比较采用独立样本 t 检验,计数资料比较采用χ2 检验。血清NGAL与各指标的相关性采用Pearson简单相关。使用Logistic回归分析相关危险因素预测MS发生风险。使用Med⁃ calc软件绘制和分析ROC曲线,判别血清NGAL及NLR在MS诊断中的价值。P< 0.05为差异有统计学意义。

  • 2 结果

  • 2.1 一般资料及生化指标比较

  • 两组间性别构成比、年龄差异无统计学意义 (P >0.05)。 MS组BMI、WC、WHR、FPG、2hPG、 SBP、DBP、FIns、2hIns、HbA1c、TG、TC、LDL ⁃ C、 HOMA⁃IR、NLR及NGAL水平高于Non⁃MS组,HDL⁃C、 HOMA⁃β水平低于Non⁃MS组,差异有统计学意义 (P <0.05或P <0.01,表1)。

  • 2.2 NGAL与各临床指标的相关性分析

  • 简单相关提示NGAL与BMI、WC、WHR、SBP、 DBP、FPG、2hPG、HbA1c、TG、HOMA ⁃ IR、NLR呈正相关(r=0.228、0.278、0.252、0.239、0.209、0.230、 0.200、0.232、0.325、0.199、0.770,P <0.05或P < 0.01),与HDL ⁃C及HOMA ⁃β呈负相关(r=-0.340、-0.193,P <0.05)。

  • 2.3 血清NGAL、NLR与MS发病风险

  • 将NGAL、NLR进行四分位分组,以是否发生MS作为因变量,分别以NGAL、NLR作为自变量,以最低分位组(Q1组)为对照,进行Logistic回归分析,校正年龄、性别后,NGAL、NLR最高分位组(Q4组) 优势比(OR)分别为11.667(3.222~42.241)、3.889 (1.083~13.964),P均<0.05(表2)。

  • 2.4 NGAL及NLR对MS发病风险的预测价值

  • NGAL联合NLR预测MS的ROC曲线下面积 (AUC)为0.683,95%CI:0.592~0.765,显著高于NGAL(AUC=0.664,95%CI:0.573~0.748)、NLR (AUC=0.598,95%CI:0.505~0.687)(P 均<0.01,表3,图1)。

  • 3 讨论

  • MS是肥胖、高血压、高血糖、血脂异常聚集的一种代谢异常状态。肥胖特别是中心性肥胖作为MS诊断的必备条件,可能是MS的基本病因之一[7]。 Wang等[8] 研究发现肥胖糖尿病小鼠肝脏和脂肪组织中的NGAL mRNA表达水平明显高于对照组。 Auguet等[9] 分别对正常体重和肥胖女性内脏及皮下脂肪组织中的NGAL mRNA及蛋白进行检测,发现后者NGAL的表达水平显著高于前者。多项人群研究[810] 也发现肥胖患者血清NGAL水平明显升高,其与血脂水平呈正相关,上述实验结果均提示,体脂增加者NGAL水平升高,并且可能与肥胖相关的代谢异常有关。本研究显示血清NGAL水平与BMI、 WC、WHR及TG等指标呈正相关,提示脂肪组织可能是肥胖状态下循环过多的NGAL的主要来源。

  • 表1 两组间一般资料及生化指标比较

  • 表2 不同血清NGAL、NLR水平与代谢综合征发生风险

  • 表3 NGAL、NLR对MS预测的ROC曲线下面积

  • 图1 NGAL、NLR及NGAL联合NLR预测MS的ROC曲线

  • 胰岛素抵抗目前被认为是MS发生、发展的中心环节。动物研究显示敲除NGAL基因的小鼠空腹血糖及胰岛素水平显著降低,胰岛素敏感性增强,同时高血压的发病风险降低[11-12]。细胞实验也证实,在3T3⁃L1脂肪细胞中降低NGAL的表达,有利于脂肪细胞摄取葡萄糖,改善胰岛素敏感性[13]。临床研究发现肥胖及2型糖尿病患者血清NGAL水平显著升高,而罗格列酮治疗显著降低了NGAL的水平[14]。目前认为NGAL通过上调12⁃脂氧合酶的活性来诱导肿瘤坏死因子⁃α(TNF⁃atumor necrosis fac⁃tor⁃α,TNF⁃α)的表达[15],以增强TNF⁃α介导的胰岛素受体底物⁃1的丝氨酸磷酸化,从而影响胰岛素受体后信号转导通路并导致胰岛素抵抗。本研究发现NGAL与血糖代谢指标及HOMA⁃IR水平正相关,与上述研究结果基本一致。此外,NGAL与血压呈正相关,目前研究提示代谢紊乱所致的高血压伴随机体内NGAL水平的升高可能与全身慢性炎症状态引起的肾损害有关[16]。以上研究结果显示,NGAL与MS密切相关。本研究中MS组血清NGAL水平高于Non⁃MS组;随着血清NGAL水平升高,MS发病风险呈上升趋势。

  • 本课题组前期研究已证实,MS的发生发展与机体慢性亚临床低度炎症状态有关[17]。慢性炎症状态的产生与免疫系统的改变有关,慢性炎症导致的白细胞数目增加,主要为非淋巴细胞如中性粒细胞等水平升高,到达炎症或感染的部位激活后续免疫细胞的招募,淋巴细胞存在消耗及增殖不足而水平下降。因此,血细胞的变化可以作为炎症指标来评价疾病的严重程度[18]。本研究结果发现,MS患者NLR水平明显升高,随着NLR水平的上升,MS的发病风险随之升高,与上述研究结果一致。此外, NGAL水平与NLR显著正相关。动物实验发现NGAL缺陷鼠脂肪组织中的12⁃脂氧合酶活性降低, TNF⁃α及白介素⁃6(interleukin⁃6,IL⁃6)显著低表达[19],人群研究也显示肥胖患者皮下脂肪组织NGAL mRNA及蛋白表达增加,其表达水平与某些炎症因子如TNF⁃α及IL⁃6正相关[920]。提示NGAL与慢性低度炎症相关,炎症可能是NGAL与MS之间联系的“桥梁”。

  • 综合NGAL、NLR与MS的密切相关性,我们推测在预测MS发生风险上,联合应用NGAL与NLR比单独应用更有优势。该研究结果表明,NGAL联合NLR预测MS的AUC为0.683,显著大于NGAL (AUC=0.664)、NLR(AUC=0.598)二者单独使用。证实两者联合预测MS的能力强于单独应用,NGAL和NLR联合使用可以作为一个识别MS高危人群的生物学指标。

  • MS和2型糖尿病、心血管及肾脏疾病的发生,以及心血管疾病病死率、全死因死亡率密切相关[21],且随着MS发病率的快速增加,带来了越来越多的社会、经济问题及家庭负担。因此,MS的早期预测、诊断具有重要意义。综上所述,本研究发现MS患者与Non⁃MS患者比较,血清NGAL及NLR水平显著上升,NGAL与NLR水平呈正相关。NGAL联合NLR作为预测MS的生物学指标优于单独使用NGAL、 NLR,为MS的临床诊断及治疗提供新依据。但也存在不足的地方,本研究为横断面研究,样本数量有限,且人群种族、地域较局限。因此,未来需要更大样本、更广泛人群及地域的前瞻性研究进一步明确血清NGAL联合NLR对评估MS的价值。

  • 参考文献

    • [1] KJELDSEN L,JOHNSEN A H,SENGELOV H,et al.Iso⁃ lation and primary structure of NGAL,a novel protein as⁃ sociated with human neutrophil gelatinase[J].J Biol Chem,1993,268(14):10425-10432

    • [2] NA G Y,YOON S R,AN J,et al.The relationship be⁃ tween circulating neutrophil gelatinase ⁃ associated lipo⁃ calin and early alteration of metabolic parameters is asso⁃ ciated with dietary saturated fat intake in non⁃diabetic Ko⁃ rean women[J].Endocr J,2017,64(3):303-314

    • [3] BHUSAL A,RAHMAN M H,LEE W H,et al.Paradoxi⁃ cal role of lipocalin⁃2 in metabolic disorders and neurolog⁃ ical complications[J].Biochem Pharmacol,2019,169:113626

    • [4] 梁利民,徐鹤翔,郑吉顺,等.RDW、NLR联合MELD评分评估失代偿期肝硬化患者预后的临床价值[J].南京医科大学学报(自然科学版),2020,40(2):217-222

    • [5] CHEN Y,YU C Y,DENG W M.The role of pro⁃inflamma⁃ tory cytokines in lipid metabolism of metabolic diseases [J].Int Rev Immunol,2019,38(6):249-266

    • [6] SYAUQY A,HSU C Y,RAU H H,et al.Association of di⁃ etary patterns,anthropometric measurements,and meta⁃ bolic parameters with C⁃reactive protein and neutrophil⁃to ⁃ lymphocyte ratio in middle ⁃ aged and older adults with metabolic syndrome in Taiwan:a cross ⁃ sectional study [J].Nutr J,2018,17(1):106

    • [7] ENGIN A.The definition and prevalence of obesity and metabolic syndrome[J].Adv Exp Med Biol,2017,960:1-17

    • [8] WANG Y,LAM K S,KRAEGEN E W,et al.Lipocalin⁃2 is an inflammatory marker closely associated with obesity,insulin resistance,and hyperglycemia in humans[J].Clin Chem,2007,53(1):34-41

    • [9] AUGUET T,QUINTERO Y,TERRA X,et a1.Upregula⁃ tion of lipocalin 2 in adipose tissues of severely obese women:positive relationship with proinflammatory cyto⁃ kines[J].Obesity(Silver Spring),2011,19(12):2295-2300

    • [10] PRADEEP A R,NAGPAL K,KARVEKAR S,et al.Lev⁃ els of lipocalin ⁃ 2 in crevicular fluid and tear fluid in chronic periodontitis and obesity subjects[J].J Investig Clin Dent,2016,7(4):376-382

    • [11] MOSIALOU I,SHIKHEL S,LUO N,et al.Lipocalin ⁃ 2 counteracts metabolic dysregulation in obesity and diabe⁃ tes[J].J Exp Med,2020,217(10):e20191261

    • [12] SONG E,FAN P,HUANG B,et al.Deamidated lipocalin⁃ 2 induces endothelial dysfunction and hypertension in di⁃ etary obese mice[J].J Am Heart Assoc,2014,3(2):e000837

    • [13] ABELLA V,SCOTECE M,CONDE J,et al.The potential of lipocalin ⁃ 2/NGAL as biomarker for inflammatory and metabolic diseases[J].Biomarkers,2015,20(8):565-571

    • [14] EILENBERG W,STOJKOVIC S,PIECHOTA ⁃ POLANC⁃ ZYK A,et al.Neutrophil gelatinase associated lipocalin(NGAL)is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment[J].Car⁃ diovasc Diabetol,2017,16(1):98

    • [15] ZHANG D,YE S,PAN T.The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J].PeerJ,2019,7:e7079

    • [16] SEIBERT F S,SITZ M,PASSFALL J,et al.Prognostic val⁃ ue of urinary calprotectin,NGAL and KIM ⁃ 1 in chronic kidney disease[J].Kidney Blood Press Res,2018,43(4):1255-1262

    • [17] YUAN G,QIAN W,PAN R,et al.Reduced circulating oxytocin and high ⁃molecular ⁃weight adiponectin are risk factors for metabolic syndrome[J].Endocr J,2016,63(7):655-662

    • [18] LIU C C,KO H J,LIU W S,et al.Neutrophil⁃to⁃lympho⁃ cyte ratio as a predictive marker of metabolic syndrome [J].Medicine(Baltimore),2019,98(43):e17537

    • [19] VICHAYA E G,GROSS P S,ESTRADA D J,et al.Lipo⁃ calin ⁃2 is dispensable in inflammation ⁃induced sickness and depression ⁃ like behavior[J].Psychopharmacology(Berl),2019,236(10):2975-2982

    • [20] SINGH R G,NGUYEN N N,CERVANTES A,et al.Cir⁃ culating levels of lipocalin⁃2 are associated with fatty pan⁃ creas but not fatty liver[J].Peptides,2019,119:170117

    • [21] JAHANGIRY L,FARHANGI M A,REZAEI F.Framing⁃ ham risk score for estimation of 10⁃years of cardiovascu⁃ lar diseases risk in patients with metabolic syndrome[J].J Health Popul Nutr,2017,36(1):36

  • 参考文献

    • [1] KJELDSEN L,JOHNSEN A H,SENGELOV H,et al.Iso⁃ lation and primary structure of NGAL,a novel protein as⁃ sociated with human neutrophil gelatinase[J].J Biol Chem,1993,268(14):10425-10432

    • [2] NA G Y,YOON S R,AN J,et al.The relationship be⁃ tween circulating neutrophil gelatinase ⁃ associated lipo⁃ calin and early alteration of metabolic parameters is asso⁃ ciated with dietary saturated fat intake in non⁃diabetic Ko⁃ rean women[J].Endocr J,2017,64(3):303-314

    • [3] BHUSAL A,RAHMAN M H,LEE W H,et al.Paradoxi⁃ cal role of lipocalin⁃2 in metabolic disorders and neurolog⁃ ical complications[J].Biochem Pharmacol,2019,169:113626

    • [4] 梁利民,徐鹤翔,郑吉顺,等.RDW、NLR联合MELD评分评估失代偿期肝硬化患者预后的临床价值[J].南京医科大学学报(自然科学版),2020,40(2):217-222

    • [5] CHEN Y,YU C Y,DENG W M.The role of pro⁃inflamma⁃ tory cytokines in lipid metabolism of metabolic diseases [J].Int Rev Immunol,2019,38(6):249-266

    • [6] SYAUQY A,HSU C Y,RAU H H,et al.Association of di⁃ etary patterns,anthropometric measurements,and meta⁃ bolic parameters with C⁃reactive protein and neutrophil⁃to ⁃ lymphocyte ratio in middle ⁃ aged and older adults with metabolic syndrome in Taiwan:a cross ⁃ sectional study [J].Nutr J,2018,17(1):106

    • [7] ENGIN A.The definition and prevalence of obesity and metabolic syndrome[J].Adv Exp Med Biol,2017,960:1-17

    • [8] WANG Y,LAM K S,KRAEGEN E W,et al.Lipocalin⁃2 is an inflammatory marker closely associated with obesity,insulin resistance,and hyperglycemia in humans[J].Clin Chem,2007,53(1):34-41

    • [9] AUGUET T,QUINTERO Y,TERRA X,et a1.Upregula⁃ tion of lipocalin 2 in adipose tissues of severely obese women:positive relationship with proinflammatory cyto⁃ kines[J].Obesity(Silver Spring),2011,19(12):2295-2300

    • [10] PRADEEP A R,NAGPAL K,KARVEKAR S,et al.Lev⁃ els of lipocalin ⁃ 2 in crevicular fluid and tear fluid in chronic periodontitis and obesity subjects[J].J Investig Clin Dent,2016,7(4):376-382

    • [11] MOSIALOU I,SHIKHEL S,LUO N,et al.Lipocalin ⁃ 2 counteracts metabolic dysregulation in obesity and diabe⁃ tes[J].J Exp Med,2020,217(10):e20191261

    • [12] SONG E,FAN P,HUANG B,et al.Deamidated lipocalin⁃ 2 induces endothelial dysfunction and hypertension in di⁃ etary obese mice[J].J Am Heart Assoc,2014,3(2):e000837

    • [13] ABELLA V,SCOTECE M,CONDE J,et al.The potential of lipocalin ⁃ 2/NGAL as biomarker for inflammatory and metabolic diseases[J].Biomarkers,2015,20(8):565-571

    • [14] EILENBERG W,STOJKOVIC S,PIECHOTA ⁃ POLANC⁃ ZYK A,et al.Neutrophil gelatinase associated lipocalin(NGAL)is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment[J].Car⁃ diovasc Diabetol,2017,16(1):98

    • [15] ZHANG D,YE S,PAN T.The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J].PeerJ,2019,7:e7079

    • [16] SEIBERT F S,SITZ M,PASSFALL J,et al.Prognostic val⁃ ue of urinary calprotectin,NGAL and KIM ⁃ 1 in chronic kidney disease[J].Kidney Blood Press Res,2018,43(4):1255-1262

    • [17] YUAN G,QIAN W,PAN R,et al.Reduced circulating oxytocin and high ⁃molecular ⁃weight adiponectin are risk factors for metabolic syndrome[J].Endocr J,2016,63(7):655-662

    • [18] LIU C C,KO H J,LIU W S,et al.Neutrophil⁃to⁃lympho⁃ cyte ratio as a predictive marker of metabolic syndrome [J].Medicine(Baltimore),2019,98(43):e17537

    • [19] VICHAYA E G,GROSS P S,ESTRADA D J,et al.Lipo⁃ calin ⁃2 is dispensable in inflammation ⁃induced sickness and depression ⁃ like behavior[J].Psychopharmacology(Berl),2019,236(10):2975-2982

    • [20] SINGH R G,NGUYEN N N,CERVANTES A,et al.Cir⁃ culating levels of lipocalin⁃2 are associated with fatty pan⁃ creas but not fatty liver[J].Peptides,2019,119:170117

    • [21] JAHANGIRY L,FARHANGI M A,REZAEI F.Framing⁃ ham risk score for estimation of 10⁃years of cardiovascu⁃ lar diseases risk in patients with metabolic syndrome[J].J Health Popul Nutr,2017,36(1):36

  • 通知关闭
    郑重声明